{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:00:17Z","timestamp":1790197217313,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Pediatric gliomas constitute the most prevalent central nervous system tumors in children, and aberrations in BRAF signaling contribute to their pathogenesis by disrupting the MAPK pathway. Targeted inhibition of this pathway using agents such as vemurafenib may hold therapeutic promise.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      PNOC002 was a multicenter trial conducted through the Pediatric Neuro-Oncology Consortium in patients younger than 25 years with recurrent or progressive BRAF\n                      <jats:sup>V600E<\/jats:sup>\n                      -mutant brain tumors. This combined phase 0\/1 study aimed to establish the recommended phase II dose (RP2D) and assess preliminary efficacy, including tumor growth trajectories and rebound (defined as \u226525% increase in lesion size within 6 months, usually within 3 months, of stopping therapy).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-patients (range, 3-23 years) were treated at the RP2D of 550 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      twice a day: 22 low-grade glioma (LGG) and 8 high-grade glioma (HGG). PFS at 6 months (PFS6) for the entire cohort was 80% (95% CI, 67 to 96). In patients with LGG, PFS6 was higher at 86% (95% CI, 73 to 100), compared with 63% (95% CI, 37 to 100) in patients with HGG. The best responses were stable disease (13 patients) and partial responses (13 patients). Four patients experienced PD, with three patients in the HGG cohort. Responsiveness varied by lesion type, with cystic lesions showing a larger and longer-lasting decrease in tumor size than solid lesions. Of 13 patients with LGG who discontinued treatment and had follow-up imaging, 3 (23%) experienced rebound within 78-97 days. The most common grade 3 adverse event was maculopapular rash (57%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Vemurafenib showed efficacy in children with recurrent or progressive BRAF\n                      <jats:sup>V600E<\/jats:sup>\n                      -mutant brain tumors with acceptable toxicity. However, the rebound rate of 23% warrants further investigation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-26-00558","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:59:13Z","timestamp":1790193553000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAF\n                    <sup>V600E<\/sup>\n                    - or BRAF\n                    <sup>InsT<\/sup>\n                    -Mutant Brain Tumors: PNOC002"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0637-1086","authenticated-orcid":true,"given":"Theodore","family":"Nicolaides","sequence":"first","affiliation":[{"name":"Caris Life Sciences, Irving, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8033-2093","authenticated-orcid":true,"given":"Raoull","family":"Hoogendijk","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, the Netherlands"},{"name":"Department of Neurology, Brain Tumor Center, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1526-2902","authenticated-orcid":true,"given":"Marie","family":"Jaeger-Krause","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4918-0167","authenticated-orcid":true,"given":"Girish","family":"Dhall","sequence":"additional","affiliation":[{"name":"Division of Hematology &amp; Oncology, University of Alabama, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Goldman","sequence":"additional","affiliation":[{"name":"Phoenix Children's Hospital, University of Arizona College of Medicine, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5019-0699","authenticated-orcid":true,"given":"Amar","family":"Gajjar","sequence":"additional","affiliation":[{"name":"St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-3619","authenticated-orcid":true,"given":"Lindsay","family":"Kilburn","sequence":"additional","affiliation":[{"name":"Center for Cancer and Blood Disorders, Brain Tumor Institute, Children's National Health System, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-6184","authenticated-orcid":true,"given":"Sarah","family":"Leary","sequence":"additional","affiliation":[{"name":"Seattle Children's Hospital, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-8761","authenticated-orcid":true,"given":"Jane","family":"Minturn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-2002","authenticated-orcid":true,"given":"Nicholas","family":"Whipple","sequence":"additional","affiliation":[{"name":"University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"Department of Radiology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janel","family":"Long-Boyle","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California San Francisco (UCSF) School of Pharmacy, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4877-8271","authenticated-orcid":true,"given":"Mariam","family":"Aboian","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9630-2075","authenticated-orcid":true,"given":"Michael","family":"Prados","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco, San Francisco, CA"},{"name":"Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9854-7404","authenticated-orcid":true,"given":"Annette M.","family":"Molinaro","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3452-5150","authenticated-orcid":true,"given":"Sabine","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco, San Francisco, CA"},{"name":"Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA"},{"name":"Department of Neurology, University of California, San Francisco, San Francisco, CA"},{"name":"University Children's Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00297-9"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1851"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1456"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0802-6"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12048"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091262"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2611"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00558"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25893"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.73"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303815"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npaf061"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2177"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","unstructured":"Nobre L Zapotocky M Ramaswamy V et al: Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis Oncol 10.1200\/PO.19.00298","DOI":"10.1200\/PO.19.00298"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27600"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1617"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae074"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae119"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24891"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1052"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1074726"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf180"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuped\/wuaf002"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.009"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30064-4"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04672-9"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213336"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061227"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02668-y"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-26-00558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:59:20Z","timestamp":1790193560000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-26-00558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1200\/PO-26-00558"],"URL":"https:\/\/doi.org\/10.1200\/po-26-00558","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2600558"}}